Biodexa Pharmaceuticals Plc (BDRX)
About Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $2.5M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $2.5M
- Shares outstanding
- 1.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 7, 2015
Biodexa Pharmaceuticals Plc (BDRX) Stock Price
- Trading 97% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Biodexa Pharmaceuticals Plc.
Write a review
News about Biodexa Pharmaceuticals Plc
News & sentiment via Polygon.io
Biodexa Pharmaceuticals Plc: frequently asked questions
Is Biodexa Pharmaceuticals Plc an American company?
Biodexa Pharmaceuticals Plc is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Biodexa Pharmaceuticals Plc publicly traded?
Yes — Biodexa Pharmaceuticals Plc is a publicly traded company. Its stock trades under the ticker symbol BDRX on the NASDAQ.
What does Biodexa Pharmaceuticals Plc do?
Biodexa Pharmaceuticals Plc is an American Pharmaceuticals company in the Health & Beauty sector.
